These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 16449248

  • 21. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization.
    Liuzzo JP, Ambrose JA, Coppola JT.
    J Invasive Cardiol; 2005 Sep; 17(9):497-502. PubMed ID: 16145242
    [Abstract] [Full Text] [Related]

  • 22. Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model.
    Huang Y, Salu K, Wang L, Liu X, Li S, Lorenz G, Wnendt S, Verbeken E, Bosmans J, Van de Werf F, De Scheerder I.
    J Invasive Cardiol; 2005 Mar; 17(3):142-8. PubMed ID: 15867441
    [Abstract] [Full Text] [Related]

  • 23. Restenosis is not associated with stent length in a pig model of coronary stent implantation.
    Koutouzis M, Papalois A, Kyrzopoulos S, Dafnomili P, Kyriakides ZS.
    Cardiol J; 2008 Mar; 15(5):458-62. PubMed ID: 18810722
    [Abstract] [Full Text] [Related]

  • 24. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.
    Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R.
    Am J Cardiol; 2007 Oct 22; 100(8B):36M-44M. PubMed ID: 17950831
    [Abstract] [Full Text] [Related]

  • 25. The Genous™ endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries.
    van Beusekom HM, Ertaş G, Sorop O, Serruys PW, van der Giessen WJ.
    Catheter Cardiovasc Interv; 2012 Feb 01; 79(2):231-42. PubMed ID: 21834062
    [Abstract] [Full Text] [Related]

  • 26. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
    Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE, ENDEAVOR III Investigators.
    J Am Coll Cardiol; 2006 Dec 19; 48(12):2440-7. PubMed ID: 17174180
    [Abstract] [Full Text] [Related]

  • 27. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.
    Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S.
    J Am Coll Cardiol; 2006 May 16; 47(10):2108-11. PubMed ID: 16697331
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial).
    Hirohata A, Morino Y, Ako J, Sakurai R, Buchbinder M, Caputo RP, Karas SP, Mishkel GJ, Mooney MR, O'shaughnessy CD, Raizner AE, Wilensky RL, Williams DO, Wong SC, Yock PG, Honda Y, Moses JW, Fitzgerald PJ, DIRECT Investigators.
    Am J Cardiol; 2006 Dec 01; 98(11):1464-7. PubMed ID: 17126651
    [Abstract] [Full Text] [Related]

  • 29. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.
    Chen YW, Smith ML, Sheets M, Ballaron S, Trevillyan JM, Burke SE, Rosenberg T, Henry C, Wagner R, Bauch J, Marsh K, Fey TA, Hsieh G, Gauvin D, Mollison KW, Carter GW, Djuric SW.
    J Cardiovasc Pharmacol; 2007 Apr 01; 49(4):228-35. PubMed ID: 17438408
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter.
    Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf D, Böhm M, Scheller B.
    Clin Res Cardiol; 2012 Jun 01; 101(6):469-76. PubMed ID: 22293991
    [Abstract] [Full Text] [Related]

  • 31. Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy.
    Yamamoto M, Okamatsu K, Inami S, Takano M, Yokoyama S, Ohba T, Ibuki C, Hata N, Seino Y, Mizuno K.
    Am Heart J; 2009 Jul 01; 158(1):99-104. PubMed ID: 19540398
    [Abstract] [Full Text] [Related]

  • 32. Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting.
    Scheller B, Schmitt A, Böhm M, Nickenig G.
    Z Kardiol; 2003 Dec 01; 92(12):1025-8. PubMed ID: 14663613
    [Abstract] [Full Text] [Related]

  • 33. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
    Souteyrand G, Levesque S, Ouchchane L, Sarry L, Eschalier R, Lusson JR, Motreff P.
    Arch Cardiovasc Dis; 2011 Mar 01; 104(3):147-54. PubMed ID: 21497303
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries.
    Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R.
    Circulation; 2009 Jul 14; 120(2):141-9, 1-2. PubMed ID: 19564562
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Zotarolimus (ABT-578) eluting stents.
    Burke SE, Kuntz RE, Schwartz LB.
    Adv Drug Deliv Rev; 2006 Jun 03; 58(3):437-46. PubMed ID: 16581153
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.